Ulcerative Colitis Diagnosis: Modern Testing & Early Detection

Ulcerative colitis diagnosis requires a multi-step approach combining clinical evaluation, blood work, stool analysis, and endoscopic visualization with biopsy confirmation. In 2026, approximately 1.2% of U.S. adults live with this chronic inflammatory condition affecting the colon’s inner lining. Early detection through comprehensive diagnostic protocols enables timely intervention whether through conventional treatments or integrative approaches like herbal TNF-α blockers significantly improving long-term quality of life and reducing the risk of severe complications.

Quick Answer: The Five-Stage Diagnostic Pathway

Getting answers about your digestive symptoms shouldn’t take months, but the path to a confirmed ulcerative colitis diagnosis typically spans several weeks. Most patients move through five distinct stages, starting with that first conversation about what’s happening in the bathroom and ending with microscopic proof from tissue samples.

According to Cdc, in 2023–2024, 1.6% of U.S. adults had ever been diagnosed with any inflammatory bowel disease (IBD), including 1.2% with ulcerative colitis and 0.5% with Crohn’s disease. These numbers underscore why systematic diagnostic protocols matter.

@keyframes hoox-lf-in-hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-top .hoox-disabled-text a:hover {
text-decoration: none;
}

Each stage builds on the previous one. Your doctor isn’t just running tests randomly they’re following evidence-based pathways that narrow down possibilities while ruling out other conditions like infectious colitis, ischemic colitis, or irritable bowel syndrome.

Stage	Component	Typical Timeframe
1	Initial Consultation & History	Day 1
2	Laboratory Tests (Blood & Stool)	3–7 days
3	Imaging Studies (CT/MRI)	1–2 weeks
4	Endoscopy (Colonoscopy/Sigmoidoscopy)	Week 2–4
5	Biopsy Confirmation	Week 4–6

The full timeline from first symptoms to confirmed UC diagnosis typically runs 2–6 weeks, though some patients face longer delays depending on appointment availability and insurance pre-authorization requirements. During this period, keeping a detailed symptom diary helps your healthcare team understand patterns in your bleeding, urgency, and stool frequency.

For patients navigating this process, understanding IBD classifications provides context for why certain tests get ordered at specific stages. The goal isn’t just labeling your condition it’s establishing a baseline that guides all future treatment decisions, from medication choices to complementary therapeutic approaches.

Why 25% of Diagnoses Happen Before Age 20

Age doesn’t protect against inflammatory bowel disease. In fact, young people represent a significant portion of new UC cases each year. According to Gitnux, about 25% of people with ulcerative colitis in the United States are diagnosed before age 20. This statistic surprises many families who assume chronic digestive conditions only affect older adults.

Pediatric and adolescent-onset UC often presents differently than adult cases. Young patients may experience more extensive colon involvement at diagnosis, and growth delays can signal disease before obvious gastrointestinal symptoms appear. Parents might notice their child eating less, losing weight, or avoiding social activities subtle changes that precede bloody stool by weeks or months.

Genetic predisposition plays a stronger role in early-onset cases. When UC appears before age 20, there’s often a family history of autoimmune conditions, though not necessarily IBD specifically. First-degree relatives of someone with ulcerative colitis face a 10–15 times higher risk of developing IBD compared to the general population.

• Family history of IBD or autoimmune conditions genetic variants affecting immune regulation
• Early antibiotic exposure altered gut microbiome during critical developmental windows
• Childhood infections triggering immune responses molecular mimicry between pathogens and gut tissue
• Environmental toxin exposure pollution and dietary factors affecting intestinal barrier function
• High-stress life events during puberty stress hormones impacting immune modulation
• Western dietary patterns processed foods, low fiber, high sugar consumption

Environmental triggers often interact with genetic susceptibility. A child genetically predisposed to immune dysregulation might never develop UC without additional triggers. But when multiple risk factors converge stress, dietary changes, infections, microbiome disruption the immune system begins attacking colon tissue.

Reading real patient experiences with early diagnosis helps families understand they’re not alone. Many young adults diagnosed in their teens or early twenties describe years of unexplained fatigue and irregular bowel habits before someone connected the dots.

Blood Work That Reveals Colon Inflammation

Blood tests can’t diagnose ulcerative colitis on their own, but they reveal critical clues about what’s happening inside your body. When your colon is inflamed, your bloodstream carries chemical signatures of that inflammation. Doctors look for patterns across multiple markers rather than relying on any single test result.

The complete blood count often shows anemia from chronic blood loss. Up to one-third of UC patients present with iron-deficiency anemia at diagnosis, caused by slow bleeding from ulcerated colon tissue. White blood cell counts may be elevated during active flares, indicating systemic immune activation.

C-reactive protein and erythrocyte sedimentation rate measure inflammation levels throughout your body. Neither test is specific to IBD, but together they provide objective measurements of disease activity. When CRP or ESR levels rise significantly, something inflammatory is happening somewhere.

Marker	Normal Range	Elevated in Active UC	Indicates
Hemoglobin	12–16 g/dL	Below normal	Chronic blood loss anemia
CRP	<10 mg/L	Often 20–100+ mg/L	Acute inflammation
ESR	<20 mm/hr	Often 30–80 mm/hr	Sustained inflammation
White Blood Cells	4,500–11,000/μL	Elevated during flares	Immune activation
Platelets	150,000–400,000/μL	Often elevated	Inflammatory response

Perinuclear anti-neutrophil cytoplasmic antibodies, or pANCA, appear in approximately 60–70% of ulcerative colitis patients. This autoantibody isn’t definitive some UC patients test negative, and some healthy people test positive but when present alongside typical symptoms, pANCA strengthens the diagnostic case.

Anti-Saccharomyces cerevisiae antibodies (ASCA) present a different pattern. ASCA positivity appears more commonly in Crohn’s disease, so when pANCA is positive and ASCA is negative, the combination supports UC over Crohn’s. These antibody panels help differentiate IBD subtypes when clinical presentation is ambiguous.

Understanding these markers helps patients explore natural anti-inflammatory solutions that work alongside conventional monitoring. Tracking inflammation markers over time provides objective feedback about whether treatments are controlling immune activity.

Fecal Calprotectin: The Non-Invasive Screening Standard

Before scheduling invasive procedures, gastroenterologists often order fecal calprotectin testing. This protein comes from neutrophils white blood cells actively fighting inflammation in your intestines. When these immune cells accumulate in colon tissue, calprotectin gets released into stool in measurable quantities.

The beauty of fecal calprotectin lies in its specificity for intestinal inflammation. Blood tests like CRP measure whole-body inflammation, which can result from infections, injuries, or chronic conditions anywhere. But calprotectin in stool directly reflects what’s happening in your digestive tract.

Results fall into interpretive ranges. Levels below 50 μg/g typically indicate absence of significant intestinal inflammation. Values between 50–150 μg/g suggest possible mild inflammation or non-IBD conditions like NSAID enteropathy. Readings above 150 μg/g strongly indicate active inflammatory bowel disease, though calprotectin can’t distinguish between UC and Crohn’s.

Sensitivity for detecting intestinal inflammation reaches approximately 90% when proper cutoff values apply. This makes fecal calprotectin an excellent screening tool. A negative result with high confidence rules out significant inflammation, potentially saving patients from unnecessary colonoscopy.

However, high calprotectin doesn’t automatically mean IBD. Infectious colitis, colorectal cancer, and NSAID-induced intestinal damage also elevate levels. The test tells doctors inflammation exists somewhere along the GI tract, prompting further investigation rather than providing definitive diagnosis.

For patients managing ongoing disease, calprotectin monitoring offers a less invasive way to assess treatment response. Rising levels may indicate impending flare before symptoms appear, allowing proactive intervention. Those interested in herbal formulations that support remission can use calprotectin trends as feedback about whether integrative approaches help maintain low inflammation states.

Colonoscopy Protocol: What Gastroenterologists Look For

Colonoscopy remains the gold standard for ulcerative colitis diagnosis. Nothing else provides direct visualization of the colon lining combined with the ability to collect tissue samples for microscopic examination. While the preparation process receives justified complaints, the procedure itself typically takes 20–45 minutes under sedation.

Gastroenterologists examine your entire colon and terminal ileum, documenting specific features that characterize UC. According to Delveinsight, in 2025, the U.S. recorded the highest number of diagnosed prevalent ulcerative colitis cases, representing nearly half of the total cases across seven major markets. This prevalence means gastroenterologists perform UC diagnostic colonoscopies routinely, developing expertise in recognizing subtle findings.

• Continuous inflammation UC affects uninterrupted segments starting from the rectum and extending proximally without skip lesions
• Diffuse erythema widespread redness indicating increased blood flow to inflamed tissue
• Friability tissue bleeds easily when touched with the endoscope, indicating severe mucosal vulnerability
• Granularity and loss of vascular pattern normal haustral folds and blood vessel visibility disappear
• Ulceration shallow erosions in the mucosal surface, ranging from pinpoint to linear

The pattern of involvement matters enormously for diagnosis. UC by definition affects only the colon, starting at the rectum and extending continuously upward. If inflammation appears patchy with healthy tissue interspersed, or if the small intestine shows involvement, doctors consider Crohn’s disease instead.

During colonoscopy, your gastroenterologist collects multiple biopsy samples from throughout the colon. Pathologists examine these tissue specimens under microscopes, looking for characteristic changes including crypt distortion, inflammation limited to the mucosa, and crypt abscesses. This histological confirmation distinguishes true IBD from infectious colitis or other mimicking conditions.

Visual findings alone can suggest UC, but biopsy results provide definitive proof. Sometimes endoscopic appearance seems classic for ulcerative colitis, but pathology reveals unexpected findings unexpected infections, medication effects, or ischemic damage. This happens more often than patients realize, which is why experienced physicians never skip biopsy confirmation.

Patients navigating this process benefit from integrative approaches to digestive health that address the whole picture, not just symptom suppression. Understanding what your colonoscopy shows helps you participate meaningfully in treatment planning.

How to Distinguish UC from Crohn’s Disease During Testing

Ulcerative colitis and Crohn’s disease both fall under the inflammatory bowel disease umbrella, but distinct diagnostic features separate them. Approximately 10–15% of IBD cases present with indeterminate colitis initially, where clear classification requires observation over time.

Location provides the clearest distinction. UC strictly affects the colon and rectum, while Crohn’s can involve any segment from mouth to anus. When colonoscopy shows terminal ileum inflammation or when imaging detects small bowel disease, the diagnosis shifts toward Crohn’s regardless of colon findings.

Feature	Ulcerative Colitis	Crohn’s Disease
Location	Colon and rectum only	Anywhere from mouth to anus
Inflammation pattern	Continuous, no skip areas	Segmental with skip lesions
Depth	Mucosa and submucosa only	Transmural (full thickness)
Rectal involvement	Almost always present	Variable, often spared
Granulomas on biopsy	Absent	Present in 30–50% of cases
Fistula/strictures	Rare	Common complications

The distribution pattern within the colon differs substantially. UC inflammation begins at the rectum and extends proximally as a continuous band. Even when disease affects only the lower colon, the involvement remains contiguous. Crohn’s disease creates patchy inflammation healthy segments interspersed with diseased areas in a pattern called “skip lesions.”

Depth of inflammation also separates these conditions. UC affects only the innermost layers the mucosa and submucosa. Crohn’s penetrates the full bowel wall thickness, which explains why Crohn’s patients develop complications like fistulas and strictures that rarely occur in UC.

Biopsy findings add diagnostic weight. Granulomas clustered immune cells forming microscopic nodules appear in approximately 30–50% of Crohn’s patients but are essentially absent in UC. Finding granulomas in colon biopsies strongly points toward Crohn’s diagnosis.

Serologic markers help when visual and histologic findings remain ambiguous. The combination of positive pANCA and negative ASCA supports UC diagnosis, while ASCA positivity with negative pANCA favors Crohn’s. These patterns aren’t definitive individually but contribute meaningful evidence to the overall diagnostic picture.

For patients seeking targeted support based on their specific IBD subtype, how Kronlitis developed targeted IBD support offers insight into formulation approaches that address colon-specific inflammation.

Key Takeaways: From Test Results to Treatment Strategy

Diagnostic testing serves one ultimate purpose informing your treatment roadmap. Every blood draw, stool sample, and tissue biopsy provides data points that guide therapeutic decisions. Understanding what your results mean helps you advocate for appropriate care.

Early diagnosis correlates with better outcomes. Patients diagnosed promptly and started on effective treatment have lower risks of complications like colon cancer, hospitalization, and surgery. The inflammatory burden accumulated over years of uncontrolled disease creates lasting damage.

• Review all test results personally request copies of lab reports and biopsy findings for your records
• Ask about inflammation marker trends single measurements matter less than patterns over time
• Discuss disease extent and severity classification know whether you have proctitis, left-sided colitis, or pancolitis
• Understand monitoring schedules surveillance colonoscopy timing depends on disease duration and extent
• Consider integrative options conventional medications work alongside complementary approaches
• Address nutritional deficiencies anemia, vitamin D, and micronutrient deficits need correction
• Establish a care team relationship IBD requires longitudinal management, so find providers you trust

Treatment strategies in 2026 span a spectrum from conventional immunosuppressive medications to integrative approaches that incorporate herbal formulations and lifestyle modification. Many patients successfully combine multiple modalities, using pharmaceutical therapies for acute control while incorporating explore natural TNF-α blocking formulations for longer-term management.

Your diagnosis isn’t just a label it’s a foundation for informed decisions. Knowing your disease location, severity, and inflammatory burden empowers you to participate in treatment planning rather than passively receiving whatever your doctor recommends.

Frequently Asked Questions About UC Diagnosis

How long does it take to get an ulcerative colitis diagnosis?

Most patients receive confirmation within 2–6 weeks after initial consultation, depending on appointment availability and insurance pre-authorization processes. The timeline extends when multiple diagnostic procedures require scheduling coordination or when initial tests prove inconclusive. Patients with classic presentations move through the pathway faster than those with ambiguous findings requiring additional specialist consultation.

Can ulcerative colitis be diagnosed without colonoscopy?

No, colonoscopy with biopsy remains essential for definitive diagnosis. Blood tests and fecal calprotectin can suggest intestinal inflammation, but they cannot distinguish ulcerative colitis from other IBD subtypes or infectious conditions. Approximately 15–20% of patients with suspected UC based on initial workup receive alternative diagnoses after colonoscopy, making the procedure irreplaceable.

What blood tests indicate ulcerative colitis?

There is no single definitive blood test for UC. Instead, doctors evaluate patterns across complete blood count, inflammatory markers (CRP and ESR), and antibody panels (pANCA and ASCA). Elevated inflammatory markers plus positive pANCA with negative ASCA strongly support UC diagnosis when combined with clinical symptoms and endoscopic findings, but blood work alone cannot diagnose the condition.

Does insurance cover diagnostic testing for UC?

Yes, most insurance plans cover medically necessary diagnostic procedures. Blood tests, fecal calprotectin, and colonoscopy for diagnostic purposes typically fall under covered services after meeting deductibles. Patients should verify specific coverage details, as some plans require pre-authorization. Out-of-pocket costs for diagnostic colonoscopy average $500–$2,000 depending on insurance structure and facility fees.

Can ulcerative colitis be misdiagnosed as irritable bowel syndrome?

Yes, IBS is a common initial misdiagnosis before UC confirmation. Studies suggest approximately 10% of patients eventually diagnosed with IBD initially received IBS labels. Fecal calprotectin testing helps differentiate these conditions IBS doesn’t cause elevated calprotectin while IBD does. Any persistent rectal bleeding should prompt investigation beyond IBS diagnosis, as bleeding isn’t an IBS symptom.

What happens after an ulcerative colitis diagnosis?

Treatment planning begins immediately after confirmation. Gastroenterologists classify disease severity and extent, then develop management strategies ranging from topical therapies for limited disease to systemic treatments for extensive involvement. Patients discuss medication options, monitoring schedules, and lifestyle modifications. Many also explore integrative approaches that complement conventional treatment for comprehensive care.

@keyframes hoox-lf-in-hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c1812c9c-c846-4a4a-bb84-0a35e6-bottom .hoox-disabled-text a:hover {
text-decoration: none;
}